Product Description: Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis[1][2][3][4].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Kim E A, et al. Lysophosphatidylcholine induces endothelial cell injury by nitric oxide production through oxidative stress [J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2009, 22(4): 325-331./[2]Liu-Wu Y, et al. Lysophosphatidylcholine induces the production of IL-1β by human monocytes [J]. Atherosclerosis, 1998, 137(2): 351-357./[3]Takahashi M, et al. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism [J]. Atherosclerosis, 2002, 161(2): 387-394./[4]Yan J J, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis [J]. Nature medicine, 2004, 10(2): 161-167.
CAS Number: 9008-30-4
Molecular Weight: N/A
Compound Purity: 99.0
Research Area: Inflammation/Immunology
Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : < 0.1 mg/mL (ultrasonic)/Methanol : 25 mg/mL (ultrasonic)
Target: Apoptosis;ERK;Interleukin Related;p38 MAPK